<DOC>
	<DOCNO>NCT00944021</DOCNO>
	<brief_summary>The trial evaluate extend bactericidal activity 14 consecutive day oral administration PA-824 50 , 100 , 150 200 mg per day adult patient newly diagnose , uncomplicated , smear positive tuberculosis ( TB ) . A control group receive standard TB treatment .</brief_summary>
	<brief_title>Evaluation Early Bactericidal Activity Pulmonary Tuberculosis ( CL-010 )</brief_title>
	<detailed_description>The planned sample size 15 participant per treatment group keep Phase II trial type account possibility 3 drop-outs per arm , base previous study type conduct site , represent conservative estimate expect drop-out rate .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<criteria>Informed Consent Body weight 40 90 kg , inclusive . Newly diagnose , previously untreated , uncomplicated , sputum smearpositive , pulmonary TB . A chest Xray compatible TB . Sputum positive Adequate volume sputum Female participant childbearing potential negative serum pregnancy agree use birth control Male participant must agree use contraception throughout participation trial 12 week last dose . Poor general condition Rifampicinresistant and/or Isoniazidresistant MTB Treatment receive within 3 month prior Allergy IMP relate substance Evidence extrathoracic TB A history previous TB Evidence serious lung condition TB uncontrolled obstructive bronchial disease History lens opacity evidence lens opacity slit lamp ophthalmologic examination Any evidence renal impairment For male , evidence history abnormality reproductive system History and/or presence ( evidence ) neuropathy epilepsy . Clinically relevant change ECG A history current clinically relevant cardiovascular disorder Concomitant use drug know prolong QTc interval Diabetics use insulin Evidence clinically significant metabolic , gastrointestinal , neurological , psychiatric endocrine disease , malignancy , abnormality ( indication study ) . Any disease condition use standard TB drug component contraindicate , include limited allergy TB drug , component IMP . Any disease condition medicinal product list section pertain prohibit medication use . alcohol drug abuse Administration IMP prior Visit 1 , within 5 halflives IMP know . If halflife IMP unknown within 1 month . Pregnant , breastfeeding , plan conceive father child within twelve week cessation treatment male within one week cessation treatment female . Use drug substance within 30 day prior dose know strong inhibitor inducer cytochrome P450 enzymes Any therapeutic agent know alter major organ function ( e.g. , barbiturate , opiate , phenothiazine , cimetidine ) within 30 day prior dose . glucocorticoid within one year prior dose . HIV infection helper/inducer T lymphocyte ( CD4 cell ) count less equal 300x106/L . Receiving antiretroviral therapy ( ART ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Early Bactericidal Activity</keyword>
	<keyword>EBA</keyword>
	<keyword>Pulmonary Tuberculosis</keyword>
	<keyword>PA-824</keyword>
	<keyword>pretomanid</keyword>
</DOC>